Summary: The Centers for Medicare & Medicaid Services modified its histocompatibility testing coverage policy, effective May 15, 2026. Here's what billing teams need to do.
CMS histocompatibility testing coverage policy changes affect transplant programs, nephrology practices, and high-complexity labs that bill Medicare for tissue typing and compatibility work. This policy does not list specific CPT or HCPCS codes in the available data — but the clinical scope is well-defined, and the billing implications are real. If your team handles organ transplant workups or stem cell transplant preparation, this modification deserves your attention before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Histocompatibility Testing |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Transplant surgery, nephrology, hematology/oncology, high-complexity laboratory, immunogenetics |
| Key Action | Audit your histocompatibility billing workflows and medical necessity documentation before May 15, 2026 |
CMS Histocompatibility Testing Coverage Criteria and Medical Necessity Requirements 2026
The Centers for Medicare & Medicaid Services governs histocompatibility testing under its national coverage framework. This testing includes HLA (human leukocyte antigen) typing, crossmatch testing, and antibody screening — all performed to assess donor-recipient compatibility before solid organ or bone marrow transplants.
Medical necessity is the core issue here. CMS generally covers histocompatibility testing when it directly supports a covered transplant procedure. That means your documentation needs to tie the testing to a specific, covered clinical purpose — not just a clinical preference or a transplant program's standing protocol.
The coverage policy requires that testing be medically necessary for the individual patient. Broad-panel typing done routinely across a transplant waiting list, without patient-specific clinical indication, sits in a gray zone. If you're billing these services without strong per-patient documentation, claim denial risk is significant.
Prior authorization is not universally required for histocompatibility testing under Medicare, but medical necessity documentation is non-negotiable. MACs — Medicare Administrative Contractors — have historically scrutinized these claims. Some MACs have issued local coverage determinations that layer additional requirements on top of CMS national policy. Check with your MAC before assuming CMS national coverage is the only standard you need to meet.
CMS Histocompatibility Testing Exclusions and Non-Covered Indications
Not every compatibility test CMS pays for. The coverage policy distinguishes between testing performed in direct support of a covered transplant and testing done for research, donor registry screening, or population-level HLA studies.
Donor registry typing — the kind done for bone marrow registries on non-patients — is not covered under Medicare's histocompatibility testing policy. Medicare covers services to Medicare beneficiaries, not to potential donors who may not be patients themselves.
Testing performed outside a transplant context also raises coverage questions. If a clinician orders HLA typing for a non-transplant indication — say, disease association studies or pharmacogenomics — that work does not fall under this coverage policy. It may have no Medicare coverage at all, or it may fall under a different, more limited LCD. Document the clinical purpose clearly, or you're billing blind.
Repeated crossmatch testing beyond what clinical criteria support is another denial trigger. CMS expects you to justify each episode of testing. "We always do it this way" is not medical necessity documentation.
Coverage Indications at a Glance
The policy data provided does not include a detailed indication-by-indication breakdown with specific codes. Based on CMS histocompatibility testing policy as it applies to Medicare billing, the general coverage framework looks like this:
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HLA typing for solid organ transplant (kidney, heart, liver, lung) | Covered | Not specified in this policy data | Must document patient-specific medical necessity |
| HLA typing for bone marrow / stem cell transplant | Covered | Not specified in this policy data | Must tie to covered transplant procedure |
| Crossmatch testing prior to transplant | Covered | Not specified in this policy data | Number of tests must be clinically justified |
| Panel reactive antibody (PRA) screening for transplant candidates | Covered | Not specified in this policy data | Per-patient documentation required |
| Donor registry HLA typing (non-patient) | Not Covered | N/A | Not a Medicare-covered service |
| Research or population-level HLA studies | Not Covered | N/A | Outside scope of this coverage policy |
| HLA typing for non-transplant indications without specific coverage | Non-covered or LCD-dependent | N/A | Verify with your MAC before billing |
Note: This policy data does not include specific CPT or HCPCS codes. See the Affected Codes section below.
CMS Histocompatibility Testing Billing Guidelines and Action Items 2026
The modified coverage policy takes effect May 15, 2026. Here's what to do between now and then.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's LCD for histocompatibility testing. CMS national policy sets the floor. Your MAC may have a local coverage determination with tighter criteria. If you bill in a region with an active LCD on this topic, that document controls your documentation requirements — not just the CMS national framework. Find your MAC at cms.gov and search their LCD database for "histocompatibility." |
| 2 | Audit your medical necessity documentation on active claims. Review claims billed in the past 90 days for HLA typing, crossmatch testing, and PRA screening. Every claim should have a documented clinical reason tied to a specific covered transplant procedure. If your documentation says "transplant workup" with nothing more specific, that's not enough. |
| 3 | Update your charge capture workflows before May 15, 2026. If your lab or hospital uses order sets or standing protocols for histocompatibility testing, review them now. Make sure each order captures the clinical indication at the patient level — not just the test type. Generic order set language won't protect you in an audit. |
| 4 | Train your transplant coordinators and lab billing staff together. The people ordering these tests and the people billing them often operate in silos. That disconnect is where denials happen. Run a joint session before the effective date. Walk through what documentation CMS requires and what your MAC's LCD says. One 60-minute session can prevent months of appeals work. |
| 5 | Build a denial tracking flag for histocompatibility claims. Starting May 15, 2026, flag any denial on these services and track the denial reason. If you see a spike in "medical necessity not established" denials after the effective date, you need to know that fast. Don't let it run for 90 days before someone notices. |
| 6 | Talk to your compliance officer if you bill high volumes of donor-side or registry-related testing. If your program does any HLA typing that isn't directly tied to an identified Medicare beneficiary and a covered transplant procedure, the coverage question is real. That's not a billing team call — loop in your compliance officer before May 15, 2026. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Histocompatibility Testing Under This Policy
Important note: The policy data provided for this CMS histocompatibility testing modification does not include specific CPT, HCPCS, or ICD-10 codes. This post does not invent or guess codes.
For the actual code set, go to the source policy at https://app.payerpolicy.org/p/cms/188-v2. You can also search CMS's published policy documents and your MAC's LCD for the applicable code lists.
What to Look For When You Pull the Code List
Histocompatibility testing typically spans several code categories. When you review the full policy, expect to find codes covering:
- HLA typing at various resolution levels (low, intermediate, high)
- Crossmatch testing (cytotoxicity-based and flow cytometry-based)
- Panel reactive antibody testing
- Molecular HLA typing
Each of those categories carries different reimbursement rates under the Medicare clinical laboratory fee schedule. Resolution level matters — high-resolution molecular typing codes typically pay more than low-resolution serology-based codes, and CMS scrutinizes whether the resolution level ordered was clinically necessary.
If your billing team isn't clear on which resolution level was performed and why, that's a documentation gap. It's also a query to the ordering clinician or the lab director before you submit the claim.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.